· Agency action
United States v. GoodRx Holdings, Inc.
Federal Trade Commission, through the Department of Justice; U.S. District Court for the Northern District of California, No. 3:23-cv-00460-DMR
Primary source: FTC case page. Checked on November 10, 2026.
In the FTC's first Health Breach Notification Rule case, GoodRx agreed to a $1.5 million civil penalty and an advertising ban over charges it disclosed users' health information to Facebook, Google and others without notice.
What happened
GoodRx Holdings, Inc. offers prescription discount coupons and, through GoodRx Care (formerly HeyDoctor), telehealth visits on its websites and apps. The Department of Justice filed the complaint for the FTC on February 1, 2023, after a 4-0 Commission vote to refer it. (Compl. paras. 2, 16, 22; FTC release, February 1, 2023.)
The complaint alleged that GoodRx promised never to share personal health information with advertisers or other third parties. It alleged that from 2017 GoodRx configured a Facebook tracking pixel to send custom events such as Drug Name and Drug Category, page URLs that often contained a medication name and, later, users' names, email addresses and phone numbers. It alleged similar sharing with Google and Criteo, and that the pixel kept sending health information for several thousand users from April to November 2020, after GoodRx said it had stopped. (Compl. paras. 27, 40-47, 57, 63.)
The complaint alleged that GoodRx used the information to target its own users with ads on Facebook and Instagram, including audiences built from medication purchase records and from visits to telehealth pages about conditions such as erectile dysfunction, HIV and pregnancy, and that it displayed a HIPAA seal although it is not a HIPAA-covered entity. (Compl. paras. 37, 48-51, 100.)
The complaint charged deception and unfairness under Section 5 of the FTC Act and, in Count VIII, a violation of the Health Breach Notification Rule for failing to notify users, the FTC and the media. GoodRx neither admitted nor denied the allegations. Commissioner Wilson concurred and wrote that she would have supported a higher civil penalty. (Compl. paras. 82-115; ECF No. 15 at 2; Wilson concurrence at 1.)
What the agency did
The order enters a $1.5 million civil penalty judgment against GoodRx. (ECF No. 15 at 22 (Section XII))
Judgment in the amount of $1,500,000 is entered in favor of Plaintiff against Defendant as a civil penalty.
ECF No. 15 at 22 (Section XII.A) GoodRx is permanently barred from disclosing health information to third parties for advertising. (ECF No. 15 at 7 (Section I.A))
permanently restrained and enjoined from disclosing Health Information to Third Parties for Advertising Purposes
ECF No. 15 at 7 (Section I.A) The order defines Health Information to include individually identifiable information derived from a person's activities that shows the person has a health condition or is taking a drug. (ECF No. 15 at 5 (Definition L))
derived or extrapolated from information about an individual’s activities, or pattern of activities, from which a determination is made that the individual has a health condition or is taking a drug
ECF No. 15 at 5 (Definition L) For the advertising ban and the consent requirement, Health Information excludes a pharmacy name (other than a specialty pharmacy tied to a specific condition) and general engagement with the site, unless that engagement reveals personal information combined with a medication the person is prescribed, has bought or is trying to obtain, or with the person's health status or a condition the person has or seeks treatment for. (ECF No. 15 at 7-9 (Sections I.C, III.C))
general engagement with or use of Defendant’s services or content, such as accessing general pricing information
ECF No. 15 at 7-8 (Section I.C) Disclosing health information to third parties for purposes other than advertising, which under the order's definitions includes advertising reporting, analytics and conversion measurement, requires affirmative express consent after a clear and conspicuous notice. Accepting general terms of use is not consent. (ECF No. 15 at 2-3, 7, 9-10 (Definition A; Sections I.B, III))
Acceptance of a general or broad terms of use or similar document that contains descriptions of agreement by the individual along with other, unrelated information, does not constitute Affirmative Express Consent.
ECF No. 15 at 2-3 (Definition A) GoodRx had to instruct third parties that received health information to delete covered information of people who used its websites or apps from July 2017 through April 2020, and to post and email those users a notice describing the FTC's allegations. (ECF No. 15 at 4, 13-14 (Definition I; Sections V, VI))
The order requires a privacy program that includes audits, reviews or testing of the web pixels and SDKs through which GoodRx shares information, with independent assessments every two years for 20 years. (ECF No. 15 at 15-19 (Sections VII, VIII))
audits, assessments, reviews, or testing of web pixels and Software Development Kits, and their associated Third Parties
ECF No. 15 at 17 (Section VII.E.9) Concurring in the settlement, Commissioner Wilson wrote that GoodRx's alleged conduct was a breach requiring notice under the rule on a plain reading of its text. (Wilson concurrence at 1 & n.2)
Under the HBNR, the alleged conduct of GoodRx constitutes a “breach” that requires notice to impacted users.
Wilson concurrence at 1
What it did not decide
- Whether GoodRx in fact violated the FTC Act or the Health Breach Notification Rule; it neither admitted nor denied the allegations, and the order's findings address jurisdiction, the charges and the parties' waivers, not the merits. (ECF No. 15 at 1-2.)
- The federal Wiretap Act, the California Invasion of Privacy Act or any other state wiretap or privacy statute; none was charged.
- Any private claim by GoodRx users; this was a government enforcement action.
- How the order's definitions would apply to any other company.
The tracking involved
Tools
- Facebook tracking pixel
- Google tracking pixel and app SDK
- Criteo
- Facebook custom audiences
- Disclosures to Branch and Twilio
Data
- Medication names and related health conditions in custom events
- Page URLs containing medication names
- Names, email addresses, phone numbers, dates of birth and ZIP codes
- IP addresses, advertising IDs and location coordinates
- Medication purchase records used to build ad audiences
How it bears on website tracking claims
Supports: strengthens a website tracking claim on this issue. Limits: narrows or defeats a website tracking claim on this issue. Context: bears on the issue without deciding it either way.
Context: Health Breach Notification Rule
The FTC rule that can treat an unauthorized disclosure of health app data as a breach that requires notice.
This was the FTC's first case under the rule (FTC release, February 1, 2023). The complaint alleged that GoodRx was a vendor of personal health records because its site and apps drew health information from users, pharmacy benefit managers, pharmacies and providers, and that its unauthorized disclosures to Facebook, Google and others were breaches of security requiring notice to users, the FTC and the media (Compl. paras. 111-113). The rule as amended in 2024 states that a breach of security includes an unauthorized acquisition resulting from an unauthorized disclosure (89 Fed. Reg. at 47054). The rule applies to vendors of personal health records and related entities that are not covered by HIPAA.
Context: Agency penalties and orders
Civil penalties, payments and conduct terms that regulators obtained.
The order enters a $1.5 million civil penalty judgment, which the FTC described as a penalty for failing to report the disclosures, and Commissioner Wilson wrote that she would have supported a higher penalty (ECF No. 15 at 22; FTC release, February 1, 2023; Wilson concurrence at 1). The amount was agreed in a stipulated order, so it does not show how a court would set a penalty.
Context: Consumer protection
Deception and unfair practice claims, such as under the FTC Act and N.Y. General Business Law § 349.
The complaint charged that GoodRx's privacy promises were deceptive and that sharing health information for advertising without notice and affirmative express consent was unfair under Section 5 of the FTC Act (Compl. paras. 82-109). The order bans disclosing health information for advertising and requires consent for other disclosures (ECF No. 15 at 7-10). It shows the FTC acting against pixel-based sharing of drug and condition information, without findings, and it does not decide any state consumer-protection statute.
Context: Health information
What counts as individually identifiable health information when it is sent through tracking tools.
The complaint alleged that custom events named Drug Name and Drug Category, and page URLs containing medication names, conveyed health information to Facebook (Compl. paras. 40-41). The order's definition covers health facts derived from a person's activities, but for the advertising ban and consent requirement it excludes general engagement with the site unless that engagement reveals personal information, which the order defines to include an IP address or a cookie identifier, combined with a medication the person is prescribed, has bought or is seeking, or with the person's health status or condition (ECF No. 15 at 5-9). That line, drawn in a negotiated order for one company, is not a court ruling, but it speaks directly to the argument that page views are not health information.
Context: Consent
Whether visitors agreed to the tracking through banners, privacy policies or terms.
The order requires affirmative express consent, after a clear and conspicuous notice given apart from any privacy policy or terms, before GoodRx discloses health information for purposes other than advertising, and it says that accepting general terms and agreement obtained through manipulated interfaces do not count (ECF No. 15 at 2-3, 9-10). The FTC's release described the latter as dark patterns. These terms bind GoodRx under the FTC Act; they do not decide consent under the Wiretap Act or a state wiretap statute.
Context: HIPAA
How HIPAA, its criminal provision at 42 U.S.C. § 1320d-6 and HHS guidance bear on tracking.
The complaint alleged that GoodRx is not a HIPAA-covered entity and that a HIPAA seal on its telehealth homepage misrepresented its status and compliance (Compl. paras. 37, 98-101). The FTC proceeded under the FTC Act and the Health Breach Notification Rule instead, and the order exempts from the consent requirement disclosures that GoodRx proves were of protected health information, made in its capacity as a HIPAA covered entity or business associate and required or permitted by the HIPAA Privacy Rule (ECF No. 15 at 10). The case does not apply HIPAA's privacy rules or 42 U.S.C. § 1320d-6.
Context: Standing and injury
Whether the people suing were harmed in a way that lets a federal court hear the claim.
The complaint alleged that the disclosures revealed details about chronic conditions, sexual and reproductive health and other sensitive matters, were likely to cause stigma, embarrassment or emotional distress, and that the failure to notify deprived users of a chance to mitigate (Compl. paras. 80-81). These are the government's allegations of consumer injury, not a ruling on Article III standing in a private suit.
Arguments it addresses
- The company is not covered by HIPAA
- The complaint alleged that GoodRx was not a HIPAA-covered entity and charged it under the FTC Act and the Health Breach Notification Rule instead (Compl. paras. 100, 111).
- Event names and URLs are just metadata
- The complaint alleged that custom events named Drug Name and Drug Category and URLs containing medication names conveyed users' health information to Facebook (Compl. paras. 40-41).
- A page visit is not health information
- For its advertising ban and consent requirement, the order excludes general engagement such as viewing general pricing information, but not when it reveals personal information, such as an IP address or cookie identifier, combined with a medication the person is prescribed, has bought or is seeking, or with the person's health status or condition (ECF No. 15 at 5-9).
- Sharing data is not a breach because nothing was hacked
- The complaint treated unauthorized disclosures to advertising platforms as breaches of security under the rule, and the rule as amended in 2024 says a breach of security includes an unauthorized acquisition resulting from an unauthorized disclosure (Compl. para. 112; 89 Fed. Reg. at 47054).
- The sharing stopped once the issue surfaced
- The complaint alleged the pixel kept sending health information for several thousand users from April to November 2020, after GoodRx said it had stopped (Compl. paras. 57, 63).
- Users agreed to the terms and privacy policy
- The order requires affirmative express consent given apart from any privacy policy or terms and says that accepting general terms of use is not consent (ECF No. 15 at 2-3).
For a company that received a letter
- The GoodRx order is a negotiated settlement without findings; it shows the FTC's position and remedies, not a court's ruling on a private claim.
- The complaint shows the FTC treating page URLs, custom event names and ad audience names as places where health information can travel.
- The Health Breach Notification Rule part of the case applies to vendors of personal health records and related entities outside HIPAA, so whether a business is one of them matters for that part.
- The order's line between general site use and information tying an identifier to a medication or condition is one way to sort which pages and events raise the issues the FTC charged.
What to check on your own site
- Check whether page addresses, page titles or custom event names sent to advertising or analytics tags include drug names, conditions or other health terms.
- Check whether advanced matching or similar settings send names, email addresses or phone numbers along with those events.
- After removing or changing a tag, test from a browser that visited the site before, since the complaint alleged that cached copies of a pixel kept sending information for months.
Later history
On March 2, 2023, on a private plaintiff's motion, the court ruled that this case is not related to two private suits against GoodRx and others, Jane Doe v. GoodRx Holdings, Inc., No. 3:23-cv-00501, and John Doe v. GoodRx Holdings, Inc., No. 4:23-cv-00744, and ordered no reassignment (ECF Nos. 16, 21). No later entry appears on the court's docket on CourtListener as of November 10, 2026, and the FTC's case page, last updated February 17, 2023, lists no later order.
Sources
- FTC case page
- Complaint (ECF No. 1)
- Stipulated order as entered (ECF No. 15, February 17, 2023; header reads No. 4:23-cv-00460-DMR)
- FTC announcement (February 1, 2023)
- Concurring statement of Commissioner Wilson (February 1, 2023)
- Federal Register: Health Breach Notification Rule (May 30, 2024)
- Court docket, No. 4:23-cv-00460-DMR (CourtListener)
Related rulings
Published by Privacy Resolve from public records. It does not cover our own matters.
General information only, not legal advice, and not a substitute for the advice of an attorney. Laws, deadlines, defenses and outcomes vary by jurisdiction and facts.